Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Recent studies prove the ancient practice of nasal irrigation is effective at fighting the common cold - 2Southern Californians, your health insurance costs could rise in 2026
- 3German finance minister sees advantages of smartphones in schools
- 4Fabricated statement about Malaysian national exam top scorers stokes racial sentiment
- 5Germany's Deutsche Welle broadcaster declared 'undesirable' in Russia
- Reporter's notebook: Inside the IDF’s ‘Hamas Village,’ and how Israel is rewriting urban warfare
- 6 Asian Urban areas to Visit
- Figure out How to Amplify the Resale Worth of Your Kona SUV
- Before Cheap Cars Were Common, This Fiat Changed Everyday Life for Millions
- NASA is shooting for the moon. A guide to the Artemis II mission
- In a scientific first, biologists recorded a wild wolf potentially using tools
- After fleeing past Hezbollah fighting, some Israelis on northern border vow to stay
- Discovery off Israel’s coast reveals earliest known 2,600-year-old shipment of raw iron
- France will build a new aircraft carrier as it increases defense spending
